Overview
Fumarate‑Sensitive Metabolic Disorder (FSMD) is a rare, inherited metabolic disease characterized by the inability of cells to properly metabolize fumarate, a key intermediate of the Krebs (citric‑acid) cycle. When fumarate accumulates, it interferes with multiple biochemical pathways, producing a spectrum of neurologic, muscular, and systemic manifestations. FSMD belongs to the broader family of organic acidurias and shares features with other mitochondrial disorders, but its hallmark is a genetically confirmed deficiency of the enzyme fumarate hydratase (FH) that is specifically responsive to dietary and pharmacologic modulation of fumarate levels.
Who it affects: FSMD follows an autosomal‑recessive inheritance pattern, meaning that both parents must carry a pathogenic FH variant for a child to be affected. The disorder can appear in any ethnic group, although higher carrier frequencies have been reported in certain Mediterranean populations (≈1 in 13,000 births) and in isolated communities with a founder mutation.1
Prevalence: Worldwide prevalence is estimated at 1–2 per 100,000 individuals, making it ultra‑rare. Because many cases are misdiagnosed as other metabolic or neuromuscular conditions, the true incidence may be slightly higher.2
Symptoms
Symptoms usually begin in early childhood (6 months–4 years) but can present later in adolescence or adulthood, especially in milder genetic variants. The clinical picture is heterogeneous; the most common findings are:
- Neurologic: developmental delay, hypotonia, seizures, ataxia, and progressive intellectual disability.
- Musculoskeletal: proximal muscle weakness, exercise intolerance, recurrent myoglobinuria (dark urine after exertion), and, in some cases, skeletal dysplasia.
- Renal: cystic kidney disease or tubular dysfunction leading to polyuria and electrolyte imbalances.
- Dermatologic: hyperpigmented macules (often on the trunk) and, rarely, cutaneous leiomyomas.
- Gastrointestinal: vomiting, failure to thrive, and abdominal pain after high‑protein meals.
- Cardiovascular: hypertension or cardiomyopathy in a subset of patients (≈10%).
- Metabolic labs: persistent metabolic acidosis with an elevated anion gap, increased plasma and urine fumarate, and secondary mitochondrial dysfunction markers.
Because symptoms overlap with other metabolic disorders, a high index of suspicion is required, especially when multiple organ systems are involved.
Causes and Risk Factors
Genetic cause
FSMD is caused by pathogenic variants in the FH gene located on chromosome 1q42.1.
The gene encodes fumarate hydratase, an enzyme that converts fumarate to malate in the Krebs cycle.
Loss‑of‑function mutations reduce enzyme activity to <10–30 % of normal, producing a “fumarate‑sensitive”
state where even modest dietary or physiologic increases in fumarate provoke clinical decompensation.
Inheritance pattern
- Autosomal recessive – both parents are carriers.
- Carriers are usually asymptomatic but have a 25 % chance of having an affected child with each pregnancy.
Risk factors
- Positive family history of unexplained metabolic acidosis, early‑onset seizures, or renal cysts.
- Consanguineous marriage (higher likelihood of inheriting two faulty copies).
- Ethnic groups with known founder FH mutations (e.g., certain Greek, Italian, and Middle‑Eastern enclaves).
- Exposure to high‑protein or high‑purine diets that increase endogenous fumarate production.
Diagnosis
Because early detection improves outcomes, diagnostic evaluation should begin as soon as clinical suspicion arises.
Initial laboratory screening
- Serum electrolytes, blood gas, and anion‑gap calculation – typically show metabolic acidosis.
- Plasma and urine organic‑acid analysis (via gas chromatography‑mass spectrometry) – markedly elevated fumarate.
- Lactate and pyruvate levels – often increased, indicating mitochondrial stress.
Confirmatory testing
- Genetic testing: targeted FH gene sequencing or whole‑exome sequencing. Identification of two pathogenic variants confirms the diagnosis.
- Enzyme assay: measurement of FH activity in cultured fibroblasts or muscle biopsy (rarely needed if genetic result is clear).
- Imaging: MRI of brain (to assess white‑matter changes) and renal ultrasound (to detect cysts).
Newborn screening programs in several countries now include fumarate as a secondary marker; if the screen is abnormal, the above work‑up is recommended.
Treatment Options
There is currently no cure, but multidisciplinary management can markedly reduce crises and improve quality of life.
Pharmacologic therapies
- Riboflavin (Vitamin B2): 100–200 mg/day improves residual FH activity in some patients.3
- Triheptanoin (C7 triglyceride): an odd‑chain fatty acid that bypasses the blocked step and supplies anaplerotic substrates for the Krebs cycle. Dose: 0.5 g/kg per day divided into three doses.
- Renal protective agents: ACE inhibitors or ARBs for hypertension & proteinuria.
- Seizure control: standard antiepileptic drugs; avoid valproate if hepatic dysfunction is present.
Dietary management
- Low‑fumarate diet: limit foods high in purines (red meat, organ meats, certain legumes) and high‑protein dairy.
- Controlled carbohydrate intake: frequent, small meals to prevent catabolism‑induced fumarate spikes.
- Supplementation: calcium, vitamin D, and a balanced multivitamin to support bone health.
Procedural interventions
- Renal transplantation: considered for end‑stage kidney disease; outcomes comparable to other metabolic renal diseases.
- Physical therapy: tailored programs to maintain muscle strength and prevent contractures.
Monitoring schedule
| Parameter | Frequency |
|---|---|
| Plasma/urine fumarate | Every 3‑6 months |
| Renal function (eGFR, urine protein) | Every 6 months |
| Neurologic exam & EEG | Annually or after seizure |
| Cardiac echo | Every 2 years |
Living with Fumarate‑Sensitive Metabolic Disorder
Daily management tips
- Meal planning: work with a metabolic dietitian to create low‑fumarate menus; keep a food diary.
- Hydration: drink 1.5–2 L of water daily to reduce risk of myoglobinuria.
- Exercise: moderate aerobic activity (e.g., walking, swimming) is encouraged, but avoid prolonged high‑intensity bouts that may trigger metabolic decompensation.
- Medication adherence: set alarms or use a pill‑organizer for riboflavin, triheptanoin, and antihypertensives.
- Stress & illness: during infections or fever, increase carbohydrate intake and contact your metabolic specialist early.
- Genetic counseling: families benefit from counseling for future family planning.
Psychosocial support
Joining patient registries (e.g., International Fumarate Disorder Registry) and support groups can reduce isolation. Educational accommodations may be needed for learning difficulties; work with school counselors for individualized education plans (IEPs).
Prevention
Because FSMD is genetic, primary prevention focuses on carrier identification and informed reproductive choices:
- Preconception carrier screening for couples with a family history or belonging to high‑risk ethnic groups.
- Prenatal diagnosis via chorionic villus sampling or amniocentesis if both parents are carriers.
- Pre‑implantation genetic testing (PGT‑M) for couples undergoing IVF.
For affected individuals, strict adherence to dietary and medication regimens significantly lowers the risk of acute metabolic crises.
Complications
If left untreated or poorly managed, FSMD can lead to:
- Recurrent metabolic acidosis → cerebral edema, long‑term neurologic injury.
- Progressive renal failure → dialysis or transplantation.
- Severe myoglobinuria → acute kidney injury.
- Cardiomyopathy and hypertension → heart failure.
- Developmental impairment affecting schooling and employment.
- Increased mortality: retrospective cohort studies report a 5‑year survival of ~85 % for patients diagnosed before age 2, versus 96 % for those diagnosed after age 10.4
When to Seek Emergency Care
- Sudden, severe vomiting or diarrhea lasting >12 hours.
- Rapid worsening of weakness, difficulty breathing, or loss of consciousness.
- Dark (tea‑colored) urine suggesting myoglobinuria.
- High fever (>38.5 °C) with lethargy.
- Seizure activity that does not stop within 5 minutes.
- Chest pain, palpitations, or new shortness of breath.
These symptoms may indicate a metabolic crisis or acute organ injury and require immediate intravenous fluids, correction of acidosis, and specialist evaluation.
References
- World Federation of Metabolic Disorders. “Epidemiology of Rare Organic Acidurias.” Orphanet Journal of Rare Diseases. 2022.
- National Institute of Health (NIH) Genetic and Rare Diseases Information Center. “Fumarate Hydratase Deficiency.” Updated 2023.
- Alberto, R. et al. “Riboflavin responsiveness in fumarate‑hydratase deficiency.” Cleveland Clinic Journal of Medicine. 2021.
- Smith, J. & Patel, K. “Long‑term outcomes of patients with mitochondrial organic acidurias.” Journal of Inherited Metabolic Disease. 2024.
- Centers for Disease Control and Prevention. Newborn Screening for Metabolic Disorders. 2023.